Literature DB >> 10340761

Receptor for the C3a anaphylatoxin is expressed by neurons and glial cells.

N Davoust1, J Jones, P F Stahel, R S Ames, S R Barnum.   

Abstract

Little is known about the expression of the receptor for complement anaphylatoxin C3a (C3aR) in the central nervous system (CNS). In this study, we provide the first evidence that neurons are the predominant cell type expressing C3aR in the normal CNS. By using in situ hybridization (ISH) and immunohistochemistry, we found that C3aR is constitutively expressed at high levels in cortical and hippocampal neurons as well as in Purkinje cells. Moreover, we showed that primary culture of human astrocytes and microglia express the C3aR mRNA as assessed by RT-PCR. In situ hybridization performed on rat primary astrocytes confirmed the RT-PCR result demonstrating C3aR expression by astrocytes. In experimental allergic encephalitis (EAE), C3aR expression was elevated on microglia, infiltrating monocyte-macrophage cells and a few astrocytes, whereas neuronal expression remained unchanged during the course of the disease. These data demonstrate that the C3aR is expressed primarily by neurons in the normal CNS and that its neuronal expression is not dramatically upregulated under inflammation. This is in contrast to the increased neuronal expression of the C5aR in several inflammatory CNS conditions. The high constitutive expression of the C3aR by neurons suggests this receptor may play an important role in normal physiological conditions in the CNS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10340761     DOI: 10.1002/(sici)1098-1136(199905)26:3<201::aid-glia2>3.0.co;2-m

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  46 in total

Review 1.  Roles of the complement system in human neurodegenerative disorders: pro-inflammatory and tissue remodeling activities.

Authors:  Philippe Gasque; Jim W Neal; Sim K Singhrao; Eamon P McGreal; Yann D Dean; Beek Johan Van; B Paul Morgan
Journal:  Mol Neurobiol       Date:  2002-02       Impact factor: 5.590

Review 2.  Complement in central nervous system inflammation.

Authors:  Scott R Barnum
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 3.  Complement in neuroprotection and neurodegeneration.

Authors:  Vijay Yanamadala; Robert M Friedlander
Journal:  Trends Mol Med       Date:  2010-01-28       Impact factor: 11.951

Review 4.  Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) disease.

Authors:  S R Barnum
Journal:  Mol Med       Date:  1999-09       Impact factor: 6.354

Review 5.  [The relevance of the inflammatory response in the injured brain].

Authors:  O I Schmidt; I Leinhase; E Hasenboehler; S J Morgan; P F Stahel
Journal:  Orthopade       Date:  2007-03       Impact factor: 1.087

Review 6.  Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.

Authors:  T V Arumugam; T M Woodruff; J D Lathia; P K Selvaraj; M P Mattson; S M Taylor
Journal:  Neuroscience       Date:  2008-07-12       Impact factor: 3.590

Review 7.  The Role of Complement C3a Receptor in Stroke.

Authors:  Saif Ahmad; Kanchan Bhatia; Adam Kindelin; Andrew F Ducruet
Journal:  Neuromolecular Med       Date:  2019-05-17       Impact factor: 3.843

8.  The receptor for the complement C3a anaphylatoxin (C3aR) provides host protection against Listeria monocytogenes-induced apoptosis.

Authors:  Stacey L Mueller-Ortiz; John E Morales; Rick A Wetsel
Journal:  J Immunol       Date:  2014-06-30       Impact factor: 5.422

9.  Evaluation of capsular and acapsular strains of S. aureus in an experimental brain abscess model.

Authors:  Nilufer Esen; Gail Wagoner; Napoleon Philips
Journal:  J Neuroimmunol       Date:  2009-11-10       Impact factor: 3.478

10.  C3aR inhibition reduces neurodegeneration in experimental lupus.

Authors:  A Jacob; L Bao; J Brorson; R J Quigg; J J Alexander
Journal:  Lupus       Date:  2009-11-09       Impact factor: 2.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.